E. Van-cutsem, A. Cervantes, R. Adam, A. Sobrero, J. H. Van-krieken et al.,

A. Aguilar, E. Bardelli, A. Benson, A. Bodoky, G. Ciardiello et al., ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

, Ann Oncol, vol.27, pp.1386-422, 2016.

L. A. Diaz, R. T. Williams, J. Wu, I. Kinde, J. R. Hecht et al.,

J. G. Reiter, M. A. Nowak, K. W. Kinzler, and K. S. Oliner, The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers, Nature, vol.486, pp.537-577, 2012.

G. Siravegna, B. Mussolin, M. Buscarino, G. Corti, A. Cassingena et al., Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients

, Nat Med, vol.21, pp.795-801, 2015.

K. G. Spindler, A. L. Appelt, N. Pallisgaard, R. F. Andersen, and A. Jakobsen, KRASmutated plasma DNA as predictor of outcome from irinotecan monotherapy in metastatic colorectal cancer, Br J Cancer, vol.109, pp.3067-72, 2013.

M. Murtaza, S. J. Dawson, D. W. Tsui, D. Gale, T. Forshew et al.,

C. , C. Sf, Z. Kingsbury, A. S. Wong, F. Marass et al., Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA, Nature, vol.497, pp.108-120, 2013.

C. Cremolini, D. Rossini, E. Dell'aquila, S. Lonardi, E. Conca et al.,

A. , P. F. Danesi, R. Aprile, G. Tamburini, E. Barone et al., Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

, JAMA Oncol, 2018.

P. Gazzaniga, C. Raimondi, F. Urbano, and E. Cortesi, EGFR Inhibitor as Second

, Line Therapy in a Patient With Mutant RAS Metastatic Colorectal Cancer: Circulating Tumor DNA to Personalize Treatment, JCO Precision Oncology, vol.2018, pp.1-6

C. Raimondi, C. Nicolazzo, F. Belardinilli, F. Loreni, A. Gradilone et al.,

A. Gelibter, G. Giannini, E. Cortesi, and P. Gazzaniga, Transient Disappearance of RAS Mutant Clones in Plasma: A Counterintuitive Clinical Use of EGFR Inhibitors in RAS Mutant Metastatic Colorectal Cancer, Cancers (Basel), vol.11, 2019.

F. Garlan, P. Laurent-puig, D. Sefrioui, N. Siauve, A. Didelot et al.,

P. Michel, G. Perkins, C. Mulot, H. Blons, J. Taieb et al., Early Evaluation of Circulating Tumor DNA as Marker of Therapeutic Efficacy in Metastatic Colorectal Cancer Patients (PLACOL Study), Clin Cancer Res, vol.23, pp.5416-5441, 2017.
URL : https://hal.archives-ouvertes.fr/inserm-02299521

J. B. Bachet, O. Bouche, J. Taieb, O. Dubreuil, M. L. Garcia et al.,

C. Gornet, J. M. Artru, P. Louafi, S. Bonnetain, F. Thirot-bidault et al., RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study, Ann Oncol, vol.29, pp.1211-1220, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02299512

S. Garrigou, G. Perkins, F. Garlan, C. Normand, A. Didelot et al., A Study of
URL : https://hal.archives-ouvertes.fr/hal-02295782

, Hypermethylated Circulating Tumor DNA as a Universal Colorectal Cancer Biomarker

, Clin Chem, vol.62, pp.1129-1168, 2016.

E. Moati, V. Taly, A. Didelot, G. Perkins, H. Blons et al.,

A. Zaanan, Role of circulating tumor DNA in the management of patients with colorectal cancer, Clin Res Hepatol Gastroenterol, vol.42, pp.396-402, 2018.
URL : https://hal.archives-ouvertes.fr/inserm-02299507

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Sci Transl Med, vol.6, pp.224-248, 2014.

R. B. Corcoran and B. A. Chabner, Application of Cell-free DNA Analysis to Cancer Treatment, N Engl J Med, vol.379, pp.1754-65, 2018.

J. G. Tate, S. Bamford, H. C. Jubb, Z. Sondka, and D. M. Beare,

H. , C. Cg, C. Creatore, E. Dawson, P. Fish et al., COSMIC: the Catalogue Of Somatic Mutations In Cancer, Nucleic Acids Res, vol.47, pp.941-948, 2019.